RegisterUpdate registrationCOUNTER ReportSwitch AccountsOpen URL ResolverChange AdministratorAccess Acknowledgement Emails PreferencesOutage Message ManagementConfigure IP addressUpdate Consortia DetailsUpdate Consortia LogoConfigure IP addressUpdate Organization DetailsUpdate Organization LogoActivate SubscriptionsSubscription DetailsRemote User AccessForgot your password?
  • Welcome Guest user
  • Register
  • Log In
  • Athens and Shibboleth Log in
    Remember me
    Log In
    Forgot your password?
  • Cart (0)
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology
  • Home
  • Essential
    Psychopharmacology 4th ed
  • The Prescriber's
    Guide 6th ed
  • Case
    Studies
    • Volume 1
    • Volume 2
  • Illustrated
    Guides
  • Other Titles
    • Violence in Psychiatry
    • The Clozapine Handbook
    • Next Generation Antidepressants
    • Self-Assessment Examination in Psychiatry
      2nd ed
    • Essential Neuropharmacology: The Prescriber's Guide
    • Prescriber's Guide - Children and Adolescents
  • Drug
    Interactions
  • Drug
    Interactions
  • My Bookmarks
  • Disclaimer
  • TOC
  • My Images
  • Preface to the Fourth Edition
  • CME Information
  • Suggested Readings
  • Index

Index

  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

The -icon indicates content; the -icon indicates figures; the -icon indicates tables.


  • major depressive disorder, , ,
  • affective symptoms,
  • as prodrome of Alzheimer’s disease,
  • disease progression concept,
  • in perimenopausal women,
  • symptom overlap with anxiety disorders,
  • use of combination antidepressant therapies,
  • mania, ,
  • and psychosis,
  • antidepressant induced,
  • antimanic actions of atypical antipsychotics,
  • in children and adolescents,
  • mild mania,
  • symptoms and circuits, . See also mood disorders
  • MAO.. monoamine oxidase
  • MAOIs.. monoamine oxidase inhibitors
  • MAPK (MAP kinase, mitogen activated protein kinase),
  • maprotiline, ,
  • marijuana,
  • and schizophrenia,
  • brain's own (anandamide),
  • effect on appetite,
  • effects of,
  • MC4R agonists,
  • MDMA (3,4-methylene-dioxymethamphetamine), ,
  • meclobemide,
  • mehylone,
  • MEK (MAP kinase/ERK kinase or mitogen-activated protein kinase kinase/extracellular signal- regulated kinase kinase),
  • melancholic depression,
  • melanin-concentrating hormone,
  • melanocyte 4 receptors (MC4Rs),
  • melatonergic hypnotics,
  • melatonin,
  • melatonin secretion
  • and depression,
  • Mellaril,
  • memantine,
  • memory disturbance.. See dementia.
  • meperidine,
  • mephedrone,
  • mescaline,
  • mesolimbic dopamine circuit
  • pathway of reward in impulsive–compulsive disorders,
  • mesoridazine,
  • metabolic disease risk
  • atypical antipsychotics,
  • metabotropic glutamate receptors (mGluRs)
  • presynaptic antagonists/postsynaptic agonists,
  • metformin,
  • methadone, ,
  • methionine synthase,
  • methionine synthase reductase,
  • methylation of histones,
  • methylenedioxypyrovalerone (MDPV),
  • methylenetetrahydrofolate reductase
  • genetic variants,
  • l-methylfolate, ,
  • mood-stabilizing properties,
  • methylphenidate, , ,
  • ADHD treatment,
  • wake-promoting agent,
  • methyltransferases,
  • methyprylon,
  • mianserin, ,
  • mild cognitive impairment (MCI)
  • distinction from normal aging,
  • milnacipran
  • properties,
  • mirtazapine, , , , , , ,
  • California rocket fuel (SNRI plus mirtazapine), ,
  • mitochondria,
  • mivacurium,
  • mixed state mood disorders, ,
  • antidepressant induced,
  • MK-4305 (suvorexant),
  • MK-6096,
  • modafinil
  • mode of action,
  • mood-stabilizing properties,
  • monoamine hypothesis of depression, ,
  • monoamine neurons
  • volume neurotransmission at autoreceptors,
  • monoamine neurotransmitters
  • and mood disorders,
  • monoamine oxidase (MAO),
  • monoamine oxidase A (MAO-A), , , ,
  • and depression,
  • reversible inhibitors of MAO-A (RIMAs),
  • monoamine oxidase B (MAO-B), , , ,
  • monoamine oxidase inhibitors (MAOIs),
  • avoidance of serotonergic agents,
  • clinical management solutions,
  • dietary tyramine interaction,
  • drug–drug interactions,
  • interactions with analgesics,
  • interactions with anesthetics,
  • interactions with decongestants,
  • interactions with opiates,
  • interactions with tricyclic antidepressants,
  • MAO-A activity and depression,
  • MAO subtypes,
  • myths and misinformation,
  • reversible inhibitors of MAO-A (RIMAs),
  • risk of hypertensive crisis,
  • risk of serotonin toxicity/serotonin syndrome,
  • switching to and from,
  • sympathomimetics to avoid or administer with caution,
  • monoamine receptor hypothesis of depression
  • and gene expression,
  • monoamine transporter blockers,
  • monoamine transporters (SLC6 family)
  • psychotropic drug targets,
  • monoamines
  • interactions between,
  • mood disorders,
  • affective symptoms of schizophrenia,
  • and hyperthymic temperament,
  • and monoamine neurotransmitters,
  • bipolar depression,
  • bipolar disorder NOS (not otherwise specified),
  • bipolar spectrum,
  • bipolar ¼ (0.25) disorder,
  • bipolar ½ (0.5) disorder,
  • bipolar I disorder,
  • bipolar I ½ (1.5) disorder,
  • bipolar II disorder,
  • bipolar II ½ (2.5) disorder,
  • bipolar III (3.0) disorder,
  • bipolar III ½ (3.5) disorder,
  • bipolar IV (4.0) disorder,
  • bipolar V (5.0) disorder,
  • bipolar VI (6.0) disorder,
  • bipolarity comorbid with dementia,
  • caused by antidepressants,
  • continuum disease model,
  • cyclothymic disorder, ,
  • depression,
  • depression symptoms and circuits,
  • depression with hypomania,
  • depressive temperament,
  • description,
  • dichotomous disease model,
  • distinguishing unipolar from bipolar depression,
  • double depression,
  • dysthymia,
  • future treatments,
  • hyperthymic temperament,
  • hypomania,
  • major depressive disorder, ,
  • mania,
  • mania symptoms and circuits,
  • mild mania,
  • mixed mood state,
  • monoamine hypothesis of depression,
  • monoamine receptor hypothesis and gene expression,
  • mood-centered perspective,
  • mood chart,
  • mood-related temperaments,
  • natural history,
  • neuroimaging,
  • neurotransmitter systems involved,
  • pain associated with,
  • pain symptoms,
  • question of progression,
  • range of moods,
  • rapid cycling,
  • related to substance abuse,
  • relationship to psychotic disorders,
  • schizoaffective disorder,
  • schizo-bipolar disorder,
  • stress and depression,
  • unipolar depression,
  • mood stabilizer selection,
  • adolescents,
  • benzodiazepines,
  • Boston bipolar brew,
  • breastfeeding patient,
  • California careful cocktail,
  • carbamazepine combinations,
  • children,
  • combinations of mood stabilizers,
  • first-line treatments in bipolar disorder,
  • innovative “eminence-based” combinations,
  • Lami-quel combination,
  • lamotrigine combinations, ,
  • lithium combinations,
  • monotherapy trials,
  • pregnant patient,
  • quetiapine combinations,
  • Tennessee mood shine,
  • valproate combinations,
  • women and bipolar disorder,
  • mood stabilizers
  • anticonvulsants,
  • antipsychotics,
  • armodafinil,
  • atypical antipsychotics,
  • benzodiazepines,
  • definitions,
  • future developments,
  • inositol,
  • lithium,
  • l-methylfolate,
  • modafinil,
  • omega-3 fatty acids (EPA and DHA),
  • risks related to antidepressants,
  • thyroid hormones,
  • morphine, ,
  • brain's own (endorphins),
  • motivational therapies,
  • motor disturbances in psychosis,
  • motor hyperactivity,
  • mRNA,
  • mTOR (mammalian target of rapamycin) pathway,
  • multi-infarct dementia
  • cognitive symptoms,
  • muscarine,
  • muscarinic cholinergic receptors,
  • blockade by conventional antipsychotics,
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 4th Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 4th Edition

ISBN: 9780511447983


$ 250
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9781107587670


$ 294
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
online@cambridge.org

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 
  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • For Librarians